Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower failure to induce endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in failure to induce global or clinical remission compared with SASP (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in failure to induce global or clinical improvement compared with SASP (high certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in failure to maintain clinical or endoscopic remission compared with conventional dosing (high certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in failure to adhere to study medication regimen compared with conventional dosing (moderate certainty).
1 finding from 1 review
Adverse event · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in adverse event compared with conventional dosing (high certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in exclusion/withdrawal after entry compared with conventional dosing (high certainty).
1 finding from 1 review
Intervention not reported
Function · participants with CTEV at initial presentation
1 finding from 1 review
Intervention not reported
Adverse events · participants with resistant CTEV
1 finding from 1 review
no estimate extracted
1 study · 4 participants
Very low
Intervention not reported
Function · participants with relapsed or recurrent CTEV
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Foot alignment · participants with relapsed or recurrent CTEV
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Gait assessment · participants with relapsed or recurrent CTEV
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Health‐related quality of life · participants with relapsed or recurrent CTEV
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · participants with relapsed or recurrent CTEV
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found